H1 2026 Financial Results
Showing 278 search results
Grifols announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in patients with emphysema due to alpha-1 antitrypsin deficiency
Grifols increases revenue by 2.6% to €3.6 billion, and net profit by 28.7% to €227 million until June
Grifols doses first patients in two Phase 3 trials to expand indications of its flagship immunoglobulins
Grifols reorganizes its operating model to accelerate execution of its strategic roadmap
Grifols doses first participant in Phase 3 study evaluating novel subcutaneous therapy for alpha1-antitrypsin deficiency
Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2025
Publications
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings annual report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.